Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.44 USD | -0.30% | -9.96% | +44.07% |
Jun. 04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
Jun. 03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
Financials (USD)
Sales 2024 * | 553M | Sales 2025 * | 592M | Capitalization | 2.31B |
---|---|---|---|---|---|
Net income 2024 * | -175M | Net income 2025 * | -188M | EV / Sales 2024 * | 4.02 x |
Net cash position 2024 * | 90.5M | Net Debt 2025 * | 59M | EV / Sales 2025 * | 4.01 x |
P/E ratio 2024 * |
-13.4
x | P/E ratio 2025 * |
-12.6
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on NovoCure Limited
1 day | -2.93% | ||
1 week | -2.32% | ||
Current month | -2.32% | ||
1 month | +33.29% | ||
3 months | +29.99% | ||
6 months | +72.00% | ||
Current year | +44.01% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 63 | 11-08-04 |
David Hung
BRD | Director/Board Member | 67 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 21 M€ | +7.83% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 21.51 | +0.05% | 185 913 |
24-06-07 | 21.5 | -2.93% | 1,193,416 |
24-06-06 | 22.15 | -4.24% | 1,045,657 |
24-06-05 | 23.13 | +1.36% | 762,100 |
24-06-04 | 22.82 | -4.48% | 1,150,047 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.01% | 2.31B | |
-24.88% | 7.32B | |
+7.04% | 6.66B | |
+15.10% | 5.5B | |
-17.63% | 4.88B | |
+14.96% | 4.1B | |
-20.83% | 3.89B | |
-25.03% | 2.83B | |
+1.73% | 2.07B | |
+9.75% | 1.97B |
- Stock Market
- Equities
- NVCR Stock